Class 4 Caution in use- Co-amoxiclav 125/31.25mg/5ml, 250/62.5mg/5ml powder for oral suspension

Sandoz limited has informed the MHRA that the products mentioned in this notification are not sugar free despite the carton stating ‘sugar free’. The ‘sugar free’ text was added to the carton in December 2008 in error.

MHRA drug alert date: 20th April 2023

MHRA drug alert link:  https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-sandoz-limited-co-amoxiclav-125-slash-31-dot-25mg-slash-5ml-250-slash-62-dot-5mg-slash-5ml-powder-for-oral-suspension-el-23-a-slash-14?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=8bedc9fd-dd67-44c7-8691-89546eb2ed97&utm_content=immediately#contents

This is a caution in use only we are not accepting stock returns.

Further Information

For more information, medical information queries, please contact: sandozgb@EU.propharmagroup.com, Telephone: +44 1276 698 101

For stock control queries, please contact: sales.sandoz-gb@sandoz.com, Telephone: +44 1276 698607